StockMacro
Menu

Acadia Pharmaceuticals

$17.11 -20% in 6 monthsMarket cap $3.0B

ACAD on XNAS, Health Care, Acadia Pharmaceuticals Inc., job postings

Measures activity, not value. Not investment advice.

Quarterly revenue rose 23% to $342.3M and 12-month profit rose 39%, but shares are down 25% in a year.

  • WatchFree cash flow was $82M over 12 months, well below reported profit

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise into making a difference for underserved neurological and rare disease communities around the world. It has two franchises in neurological and rare diseases. Its neurological disease franchise is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. FDA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Industry
Pharmaceutical preparations (Health Care)
Employees
798
Website
acadia.com
Listed
Nasdaq, US
Last results
4 Nov 2026
Next results
expected around 12 Jan 2027 (an estimate: a year ago it reported on 13 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $342.3M, net income $53.5M.
Quarter to 31 Dec 2021: revenue $130.8M, net income -$43.1MQuarter to 31 Dec 2021: revenue $130.8M, net income -$43.1MQuarter to 31 Mar 2022: revenue $115.5M, net income -$113.1MQuarter to 31 Mar 2022: revenue $115.5M, net income -$113.1MQuarter to 30 Jun 2022: revenue $134.6M, net income -$34.0MQuarter to 30 Jun 2022: revenue $134.6M, net income -$34.0MQuarter to 30 Sep 2022: revenue $130.7M, net income -$27.2MQuarter to 30 Sep 2022: revenue $130.7M, net income -$27.2MQuarter to 31 Dec 2022: revenue $136.5M, net income -$41.7MQuarter to 31 Dec 2022: revenue $136.5M, net income -$41.7MQuarter to 31 Mar 2023: revenue $118.5M, net income -$43.0MQuarter to 31 Mar 2023: revenue $118.5M, net income -$43.0MQuarter to 30 Jun 2023: revenue $165.2M, net income $1.1MQuarter to 30 Jun 2023: revenue $165.2M, net income $1.1MQuarter to 30 Sep 2023: revenue $211.7M, net income -$65.2MQuarter to 30 Sep 2023: revenue $211.7M, net income -$65.2MQuarter to 31 Dec 2023: revenue $231.0M, net income $45.8MQuarter to 31 Dec 2023: revenue $231.0M, net income $45.8MQuarter to 31 Mar 2024: revenue $205.8M, net income $16.6MQuarter to 31 Mar 2024: revenue $205.8M, net income $16.6MQuarter to 30 Jun 2024: revenue $242.0M, net income $33.4MQuarter to 30 Jun 2024: revenue $242.0M, net income $33.4MQuarter to 30 Sep 2024: revenue $250.4M, net income $32.8MQuarter to 30 Sep 2024: revenue $250.4M, net income $32.8MQuarter to 31 Dec 2024: revenue $259.6M, net income $143.7MQuarter to 31 Dec 2024: revenue $259.6M, net income $143.7MQuarter to 31 Mar 2025: revenue $244.3M, net income $19.0MQuarter to 31 Mar 2025: revenue $244.3M, net income $19.0MQuarter to 30 Jun 2025: revenue $264.6M, net income $26.7MQuarter to 30 Jun 2025: revenue $264.6M, net income $26.7MQuarter to 30 Sep 2025: revenue $278.6M, net income $71.8MQuarter to 30 Sep 2025: revenue $278.6M, net income $71.8MQuarter to 31 Dec 2025: revenue $284.0M, net income $273.6MQuarter to 31 Dec 2025: revenue $284.0M, net income $273.6MQuarter to 31 Mar 2026: revenue $268.1M, net income $3.6MQuarter to 31 Mar 2026: revenue $268.1M, net income $3.6MQuarter to 30 Jun 2026: revenue $308.0M, net income $31.5MQuarter to 30 Jun 2026: revenue $308.0M, net income $31.5MQuarter to 30 Sep 2026: revenue $342.3M, net income $53.5MQuarter to 30 Sep 2026: revenue $342.3M, net income $53.5M
31 Dec 2021RevenueNet incomeNet losstallest bar $342.3M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$342.3M$53.5M
30 Jun 2026$308.0M$31.5M
31 Mar 2026$268.1M$3.6M
31 Dec 2025$284.0M$273.6M
30 Sep 2025$278.6M$71.8M
30 Jun 2025$264.6M$26.7M
31 Mar 2025$244.3M$19.0M
31 Dec 2024$259.6M$143.7M
30 Sep 2024$250.4M$32.8M
30 Jun 2024$242.0M$33.4M
31 Mar 2024$205.8M$16.6M
31 Dec 2023$231.0M$45.8M
30 Sep 2023$211.7M-$65.2M
30 Jun 2023$165.2M$1.1M
31 Mar 2023$118.5M-$43.0M
31 Dec 2022$136.5M-$41.7M
30 Sep 2022$130.7M-$27.2M
30 Jun 2022$134.6M-$34.0M
31 Mar 2022$115.5M-$113.1M
31 Dec 2021$130.8M-$43.1M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $1.2B $1.0B
Revenue growthRevenue of the last 12 months compared with the 12 months before. +15% +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $362.2M $261.2M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $2.12 $1.55
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 90.5% 91.9% 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 10.2% 23.0% -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 30.1% 24.9% -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. 31.4% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $82.0M $197.8M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $976.4M $847.0M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$976.4M (net cash) -$847.0M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $8.03
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 8.2 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. 2.5 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 1.6 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 2.1 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Acadia PharmaceuticalsACAD (this company) $3.0B8.22.5+15%30.1%
Dyne TherapeuticsDYN $2.9Bloss–––
Bausch Health CompaniesBHC $3.1Bloss0.28+11%-7.6%
Xeris BiopharmaXERS $3.1Bloss8.4+38%-1.8%
SELLAS Life SciencesSLS $2.8Bloss–––
Viking TherapeuticsVKTX $3.2Bloss–––

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$69K

bought $0, sold $69K

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

0%

346 13F filers vs 346

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

96%

166.4M shares held by 13F filers (30 Sep 2026) of 172.8M outstanding (28 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

4.8%

8.3M shares sold short (30 Oct 2026) of 172.8M outstanding (28 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

5.9

8.3M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-8.5%

9.1M shares sold short in the report before, 8.3M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

46%

46% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 47%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

35

Tracked since 20 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 20 Nov 2026; the change shows after 30 days.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+23%

$342.3M vs $278.6M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$2.3M

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

20

20 articles in the last 7 days; its usual week has 5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

4.0×

20 articles in the last 7 days; its usual week has 5.

Price $17.11 on 20 Nov 2026, -25% over 12 months (12-month range $16.50 to $30.57)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $2.5M in the last 12 months (the 12 months before: -$2.5M).
Revenue per quarter. Revenue $342.3M in the latest quarter, +23% on a year earlier.
Capital spending per quarter. Capital spending $1.2M in the latest quarter, +220% on a year earlier.
Institutional holders (13F filers). 346 13F filers reported holding it in the latest 13F quarter, +8.5% on a year earlier.
Lobbying spend. Lobbying spend: $2.3M published in the last 12 months, +5.9% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
23 Oct 20268-K and other filingsDirector or officer change
23 Oct 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
6 Aug 2026Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 5.1M vs usual 342K (2026-06-30); 17.1x the same period a year earlier
29 May 20268-K and other filingsDirector or officer change
12 May 2026Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 5.2M vs usual 184K (2026-03-31)
30 Apr 20268-K and other filingsDirector or officer change
16 Apr 2026Lobbying filinglobbying engagement terminated (LMH STRATEGIC SOLUTIONS)
5 Mar 20268-K and other filingsDirector or officer change
5 Mar 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
20 Jan 2026Lobbying filinglobbying engagement terminated (THE CONAFAY GROUP, LLC)
3 Nov 20258-K and other filingsDirector or officer change
3 Nov 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
21 Jul 2025Sharp changeLobbying on a new issue: lobbying on a new issue: PHA (2025-06-30)
16 Jul 2025Lobbying filingnew lobbying registration (LMH STRATEGIC SOLUTIONS)
15 May 2025Sharp changeMany funds opening a new position: many funds opening a new position, 57 vs usual 32.50 (2025-03-31); 1.4x the same period a year earlier
18 Feb 2025Sharp changeMany funds opening a new position: many funds opening a new position, 51 vs usual 31.50 (2024-12-31); 1.1x the same period a year earlier
28 Jan 2025Sharp changeShort interest spike: short interest spike, 17.1M vs usual 10.6M (2025-01-15); 2.1x the same period a year earlier
21 Jan 2025Sharp changeLobbying spend jump: lobbying spend jump, 510K vs usual 245K (2024-12-31); 2.1x the same period a year earlier
20 Jan 2025Sharp changeLobbying on a new issue: lobbying on a new issue: TAX (2024-12-31)
9 Jan 2025Lobbying filingnew lobbying registration (HOLLAND & KNIGHT LLP)
11 Dec 20248-K and other filingsCompleted an acquisition or asset sale
20 Nov 20248-K and other filingsDirector or officer change
21 Oct 2024Sharp changeLobbying on a new issue: lobbying on a new issue: TRD (2024-09-30)
23 Sep 20248-K and other filingsDirector or officer change
23 Sep 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
23 Jul 2024Sharp changeLobbying spend jump: lobbying spend jump, 450K vs usual 245K (2024-06-30); 2.0x the same period a year earlier
29 May 20248-K and other filingsDirector or officer change
29 May 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
5 Mar 2024Sharp changeQuarterly revenue change: quarterly revenue change, 231.0M vs usual 132.7M (2023-12-31); 1.7x the same period a year earlier
20 Feb 2024Sharp changeMany funds opening a new position: many funds opening a new position, 48 vs usual 30.50 (2023-12-31); 2.1x the same period a year earlier
31 Jan 20248-K and other filingsDirector or officer change
31 Jan 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
7 Nov 2023Sharp changeQuarterly revenue change: quarterly revenue change, 211.7M vs usual 131.2M (2023-09-30); 1.6x the same period a year earlier
24 Jan 2023Sharp changeLobbying spend jump: lobbying spend jump, 370K vs usual 215K (2022-12-31); 1.9x the same period a year earlier
28 Oct 20228-K and other filingsDirector or officer change
20 Oct 2022Sharp changeLobbying on a new issue: lobbying on a new issue: BUD, DEF (2022-09-30)
13 Oct 20228-K and other filingsDirector or officer change
13 Oct 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Jun 2022Sharp changeShort interest spike: short interest spike, 12.9M vs usual 7.2M (2022-05-31); 2.2x the same period a year earlier
10 Jun 20228-K and other filingsDirector or officer change
31 May 2022Sharp changeShort interest spike: short interest spike, 13.0M vs usual 7.2M (2022-05-13); 1.8x the same period a year earlier
17 May 2022Sharp changeShort interest spike: short interest spike, 12.0M vs usual 7.2M (2022-04-29); 1.6x the same period a year earlier
8 Apr 20228-K and other filingsDirector or officer change
8 Apr 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Dec 20218-K and other filingsDirector or officer change
Insider net buying (open market)
Month from 1 Nov 2021: -$53K published
Month from 1 Jan 2022: -$156K published
Month from 1 Feb 2022: -$181K published
Month from 1 Apr 2022: -$28K published
Month from 1 May 2022: -$178K published
Month from 1 Jun 2022: -$12K published
Month from 1 Oct 2022: -$65K published
Month from 1 Nov 2022: -$28K published
Month from 1 Jan 2023: -$314K published
Month from 1 Feb 2023: -$113K published
Month from 1 Apr 2023: -$271K published
Month from 1 May 2023: $21.7M published
Month from 1 Jun 2023: -$185K published
Month from 1 Jul 2023: -$4.8M published
Month from 1 Aug 2023: -$290K published
Month from 1 Sep 2023: -$52K published
Month from 1 Oct 2023: -$1.5M published
Month from 1 Nov 2023: -$273K published
Month from 1 Dec 2023: -$57K published
Month from 1 Jan 2024: -$151K published
Month from 1 Feb 2024: -$184K published
Month from 1 Mar 2024: -$506K published
Month from 1 Apr 2024: -$601K published
Month from 1 May 2024: -$334K published
Month from 1 Jun 2024: -$14K published
Month from 1 Aug 2024: -$779K published
Month from 1 Nov 2024: -$415K published
Month from 1 Feb 2025: -$25K published
Month from 1 Mar 2025: -$162K published
Month from 1 Apr 2025: -$55K published
Month from 1 May 2025: -$210K published
Month from 1 Jun 2025: -$315K published
Month from 1 Aug 2025: -$554K published
Month from 1 Sep 2025: -$124K published
Month from 1 Nov 2025: -$1.0M published
Month from 1 Feb 2026: -$162K published
Month from 1 Mar 2026: -$607K published
Month from 1 Apr 2026: -$83K published
Month from 1 May 2026: -$220K published
Month from 1 Jun 2026: -$298K published
Month from 1 Aug 2026: -$1.0M published
Month from 1 Oct 2026: -$69K published
Revenue per quarter
Quarter ended 31 Dec 2021: $130.8M, +8.1% on a year earlier; public on 2 Mar 2022
Quarter ended 31 Mar 2022: $115.5M, +8.4% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $134.6M, +17% on a year earlier; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $130.7M, -0.7% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $136.5M, +4.4% on a year earlier; public on 1 Mar 2023
Quarter ended 31 Mar 2023: $118.5M, +2.6% on a year earlier; public on 9 May 2023
Quarter ended 30 Jun 2023: $165.2M, +23% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $211.7M, +62% on a year earlier; public on 4 Nov 2023
Quarter ended 31 Dec 2023: $231.0M, +69% on a year earlier; public on 29 Feb 2024
Quarter ended 31 Mar 2024: $205.8M, +74% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $242.0M, +46% on a year earlier; public on 8 Aug 2024
Quarter ended 30 Sep 2024: $250.4M, +18% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $259.6M, +12% on a year earlier; public on 28 Feb 2025
Quarter ended 31 Mar 2025: $244.3M, +19% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $264.6M, +9.3% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $278.6M, +11% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $284.0M, +9.4% on a year earlier; public on 27 Feb 2026
Quarter ended 31 Mar 2026: $268.1M, +9.7% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $308.0M, +16% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $342.3M, +23% on a year earlier; public on 6 Nov 2026
Capital spending per quarter
Quarter ended 31 Mar 2022: $0, -100% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $0, -100% on a year earlier; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $0; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $0; public on 1 Mar 2023
Quarter ended 31 Dec 2023: $0; public on 29 Feb 2024
Quarter ended 30 Sep 2024: $70K; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $453K; public on 28 Feb 2025
Quarter ended 31 Mar 2025: $0; public on 8 May 2026
Quarter ended 30 Jun 2025: $297K; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $388K, +454% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Mar 2026: $5.2M; public on 8 May 2026
Quarter ended 30 Jun 2026: $5.1M, +1613% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $1.2M, +220% on a year earlier; public on 6 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 224; public on 14 Feb 2022
31 Mar 2022 report: 250; public on 16 May 2022
30 Jun 2022 report: 234; public on 15 Aug 2022
30 Sep 2022 report: 202; public on 14 Nov 2022
31 Dec 2022 report: 210; public on 14 Feb 2023
31 Mar 2023 report: 218; public on 15 May 2023
30 Jun 2023 report: 219; public on 14 Aug 2023
30 Sep 2023 report: 226; public on 14 Nov 2023
31 Dec 2023 report: 258; public on 14 Feb 2024
31 Mar 2024 report: 254; public on 15 May 2024
30 Jun 2024 report: 249; public on 14 Aug 2024
30 Sep 2024 report: 248; public on 14 Nov 2024
31 Dec 2024 report: 285; public on 14 Feb 2025
31 Mar 2025 report: 305; public on 15 May 2025
30 Jun 2025 report: 295; public on 14 Aug 2025
30 Sep 2025 report: 319; public on 14 Nov 2025
31 Dec 2025 report: 322; public on 17 Feb 2026
31 Mar 2026 report: 330; public on 15 May 2026
30 Jun 2026 report: 346; public on 14 Aug 2026
30 Sep 2026 report: 346; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $200K published
Quarter from 1 Jul 2022: $540K published
Quarter from 1 Oct 2022: $260K published
Quarter from 1 Jan 2023: $370K published
Quarter from 1 Apr 2023: $390K published
Quarter from 1 Jul 2023: $230K published
Quarter from 1 Oct 2023: $180K published
Quarter from 1 Jan 2024: $240K published
Quarter from 1 Apr 2024: $250K published
Quarter from 1 Jul 2024: $450K published
Quarter from 1 Oct 2024: $220K published
Quarter from 1 Jan 2025: $510K published
Quarter from 1 Apr 2025: $440K published
Quarter from 1 Jul 2025: $500K published
Quarter from 1 Oct 2025: $750K published
Quarter from 1 Jan 2026: $590K published
Quarter from 1 Apr 2026: $600K published
Quarter from 1 Jul 2026: $700K published
Quarter from 1 Oct 2026: $440K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is revenue, quarter at $342.3M (30 Sep 2026), 1.3× its normal quarter; higher than 100% of its own history.
  • Quarterly capital spending jump: spent $5.1M on capital projects in the quarter ended 30 Jun 2026, 17× the same quarter last year Public on 6 Aug 2026.
  • Insider net buying (open market): Insiders sold a net $2.5M in the last 12 months (the 12 months before: -$2.5M).
  • Revenue per quarter: Revenue $342.3M in the latest quarter, +23% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 1 sale, $69K; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
30 Oct 2026Mark C. SchneyerEVP, CHIEF FINANCIAL OFFICERSell3,321$20.88$69KForm 4
7 Aug 2026Mark C. SchneyerEVP, CHIEF FINANCIAL OFFICERSellplanned in advance (10b5-1); after exercising options20,141$29.16$587KForm 4
31 Jul 2026Elizabeth H.z. ThompsonEVP, Head of Research & DevSellafter exercising options16,558$26.13$433KForm 4
29 Jun 2026James KiharaPRINCIPAL ACCOUNTING OFFICERSellplanned in advance (10b5-1)11,421$26.08$298KForm 4
27 May 2026James KiharaPRINCIPAL ACCOUNTING OFFICERSell5,401$21.18$114KForm 4
5 May 2026James KiharaPRINCIPAL ACCOUNTING OFFICERSellafter exercising options1,332$21.79$29KForm 4
5 May 2026Mark C. SchneyerEVP, CHIEF FINANCIAL OFFICERSellafter exercising options3,506$21.79$76KForm 4
7 Apr 2026Mark C. SchneyerEVP, CHIEF FINANCIAL OFFICERSellafter exercising options2,709$22.20$60KForm 4

346 institutions reported shares at the end of Q3 2026, 96% of the shares outstanding; 52 opened a position, 58 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Baker Bros. Advisors LP42.9M24.8%$864.7MNo change
BlackRock, Inc.22.9M13.3%$462.4M+432K+1.9%
Vanguard Portfolio Management LLC9.5M5.47%$190.6M+619K+7.0%
State Street Corp7.7M4.43%$154.2M-1.4M-16%
RTW Investments, LP7.1M4.13%$144.0MNo change
Vanguard Capital Management LLC5.8M3.35%$116.7M+27K+0.5%
Goldman Sachs Group Inc4.6M2.67%$93.1M+2.0M+79%
Geode Capital Management, LLC3.4M1.95%$68.0M+14K+0.4%
Dimensional Fund Advisors LP3.4M1.95%$67.8M-329K-8.9%
Palo Alto Investors LP2.5M1.44%$50.1M-378K-13%

Company events

All 40 company events

In 12 months: 4 director or officer changes. Results releases and routine reports are left out.

FiledWhat happenedSource
23 Oct 2026Director or officer change8-K
29 May 2026Director or officer changeSame filing: shareholder vote results8-K
30 Apr 2026Director or officer change8-K
4 Mar 2026Director or officer change8-K
3 Nov 2025Director or officer change8-K
20 May 2025Signed a major agreement8-K
11 Dec 2024Completed an acquisition or asset sale8-K
20 Nov 2024Director or officer change8-K

35 open postings; careers site tracked since 20 Nov 2026. Most in Sales & business development 31%, Legal, policy & compliance 14%, Program & project management 14%, Research & science 14%.

PostedJobLocation
20 Nov 2026Manager, Compliance OperationsLegal, policy & complianceSan Diego, California, United States
20 Nov 2026Patient Access Manager - Boston, MAProgram & project managementMassachusetts - Remote
16 Nov 2026Sr. Manager, FP&A - CommercialFinance & accountingPrinceton, New Jersey, United States
6 Nov 2026Director, Global PV ManagementLegal, policy & compliancePrinceton, New Jersey, United States; San Diego, California, United States; South San Francisco, California, United States
6 Nov 2026Family Support Educator (FSE) - Atlanta, GAProgram & project managementAlabama - Remote; Georgia - Remote; Mississippi - Remote
5 Nov 2026Executive Neuroscience Sales Specialist, Raleigh, NCSales & business developmentNorth Carolina - Remote
4 Nov 2026Sr. Medical Director, GermanyProgram & project managementMunich, Bavaria, Germany
3 Nov 2026Executive Long-Term Care Sales Specialist - Long Island, NYSales & business developmentNew York - Remote

Reported lobbying spend: $440K in Q3 2026, $700K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
31 Dec 2025EndedLMH Strategic Solutionsfor Acadia PharmaceuticalsGeneral Medicare and Medicaid Issues.; Prescription drug payment reform. Pharmaceutical supply chain.Medicare/Medicaid, PharmacyFiling
31 Dec 2025EndedThe Conafay Group, LLCfor Acadia Pharmaceuticals Inc.Support for biomedical research.; Medicare and Medicaid Reform.MED, Medicare/MedicaidFiling
1 Jun 2025NewLMH Strategic Solutionsfor Acadia PharmaceuticalsGeneral Medicare and Medicaid Issues. Prescription drug payment reform. Pharmaceutical supply chain.Medicare/Medicaid, PharmacyFiling
12 Nov 2024NewHolland & Knight LLPfor Acadia Pharmaceuticals Inc.Tax Reform - Restoring the Orphan Drug Tax Credit.TaxationFiling
1 Jan 2021EndedTiber Creek Health Strategies, Inc.for Peck Madigan Jones (On Behalf Of Acadia Pharmaceuticals, Inc.)Not statedFiling
27 Oct 2020NewAcadia Pharmaceuticalsits own lobbyistsIssues affecting the pharmaceutical industryHealth issues, Medicare/MedicaidFiling
6 Oct 2020NewTiber Creek Health Strategies, Inc.for Peck Madigan Jones (On Behalf Of Acadia Pharmaceuticals, Inc.)Issues affecting the pharmaceutical industry.Health issuesFiling
6 Oct 2020NewTiber Creek Groupfor Acadia Pharmaceuticals, Inc.Issues affecting the pharmaceutical industry.Health issuesFiling

The 5 newest of 240 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

28 Jan 2025confirmed

Confirmed across sources Institutional holdings and Lobbying and Short interest and volume

Acadia Pharmaceuticals (ACAD): reported $510K of lobbying spend for the quarter ended 31 Dec 2024, 2.1× the same quarter last year; it also had 17.1M shares sold short in the 15 Jan 2025 report, 2.1× the same report last year; and it saw 51 13F filers open a new position in the quarter ended 31 Dec 2024, 1.1× the same quarter last year. Three unrelated kinds of activity within 29 days.

  • Lobbying: Lobbying on a new issue, became public on 20 Jan 2025
  • Lobbying: Lobbying spend jump, became public on 20 Jan 2025
  • Short interest and volume: Short interest spike, became public on 28 Jan 2025
  • Institutional holdings: Many funds opening a new position, became public on 14 Feb 2025
2022-12-31: $370K2023-03-31: $390K2023-06-30: $230K2023-09-30: $180K2023-12-31: $240K2024-03-31: $250K2024-06-30: $450K2024-09-30: $220K2024-12-31: $510K
The quarter ended 31 Dec 2024 against the 8 quarters before it. this quarterearliernormal: $245K
See the evidence (4 changes)

Lobbying: Lobbying on a new issue became public on 20 Jan 2025

Acadia Pharmaceuticals lobbying on a new issue.

New
['TAX']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
6272795

Lobbying: Lobbying spend jump became public on 20 Jan 2025

Acadia Pharmaceuticals reported $510K of lobbying spend for the quarter ended 31 Dec 2024, 2.1× the same quarter last year.

This period
$510K (the quarter ended 31 Dec 2024)
Normal quarter (median of 8 earlier)
$245K
Typical spread (median absolute deviation)
$45K
How far from its usual level
+4.0
Same quarter last year
$240K
History used
2,284 days
2022-12-31: $370K2023-03-31: $390K2023-06-30: $230K2023-09-30: $180K2023-12-31: $240K2024-03-31: $250K2024-06-30: $450K2024-09-30: $220K2024-12-31: $510K
the quarter ended 31 Dec 20248 earlier quartersnormal: $245K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

Check it at the source: Senate/House lobbying disclosures (LDA).

Short interest and volume: Short interest spike became public on 28 Jan 2025

Acadia Pharmaceuticals had 17.1M shares sold short in the 15 Jan 2025 report, 2.1× the same report last year.

This period
17.1M (the 15 Jan 2025 report)
Normal report (median of 24 earlier)
10.6M
Typical spread (median absolute deviation)
1.2M
How far from its usual level
+3.7
Same report last year
8.1M
History used
2,574 days
2024-01-12: 8.1M2024-01-31: 7.7M2024-02-15: 9.4M2024-02-29: 10.8M2024-03-15: 10.6M2024-03-28: 11.2M2024-04-15: 11.2M2024-04-30: 12.0M2024-05-15: 12.0M2024-05-31: 12.1M2024-06-14: 12.6M2024-06-28: 11.9M2024-07-15: 11.3M2024-07-31: 11.5M2024-08-15: 10.7M2024-08-30: 10.3M2024-09-13: 9.2M2024-09-30: 8.0M2024-10-15: 8.2M2024-10-31: 9.5M2024-11-15: 10.2M2024-11-29: 9.9M2024-12-13: 9.4M2024-12-31: 10.7M2025-01-15: 17.1M
the 15 Jan 2025 report24 earlier reportsnormal: 10.6M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Institutional holdings: Many funds opening a new position became public on 14 Feb 2025

Acadia Pharmaceuticals saw 51 13F filers open a new position in the quarter ended 31 Dec 2024, 1.1× the same quarter last year.

This period
51 (the quarter ended 31 Dec 2024)
Normal quarter (median of 8 earlier)
31.5
Typical spread (median absolute deviation)
2.5
How far from its usual level
+5.3
Same quarter last year
48
History used
4,110 days
2022-12-31: 232023-03-31: 332023-06-30: 302023-09-30: 312023-12-31: 482024-03-31: 402024-06-30: 322024-09-30: 282024-12-31: 51
the quarter ended 31 Dec 20248 earlier quartersnormal: 31.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

5 Mar 2024confirmed

Confirmed across sources Institutional holdings and Filings + Financials

Acadia Pharmaceuticals (ACAD): saw 48 13F filers open a new position in the quarter ended 31 Dec 2023, 2.1× the same quarter last year, while it reported revenue of $231.0M for the quarter ended 31 Dec 2023, 1.7× the same quarter last year. Two unrelated kinds of activity within 14 days.

  • Institutional holdings: Many funds opening a new position, became public on 14 Feb 2024
  • Financials: Quarterly revenue change, became public on 5 Mar 2024
2021-12-31: 332022-03-31: 412022-06-30: 302022-09-30: 202022-12-31: 232023-03-31: 332023-06-30: 302023-09-30: 312023-12-31: 48
The quarter ended 31 Dec 2023 against the 8 quarters before it. this quarterearliernormal: 30.5
See the evidence (2 changes)

Institutional holdings: Many funds opening a new position became public on 14 Feb 2024

Acadia Pharmaceuticals saw 48 13F filers open a new position in the quarter ended 31 Dec 2023, 2.1× the same quarter last year.

This period
48 (the quarter ended 31 Dec 2023)
Normal quarter (median of 8 earlier)
30.5
Typical spread (median absolute deviation)
2.5
How far from its usual level
+4.7
Same quarter last year
23
History used
3,744 days
2021-12-31: 332022-03-31: 412022-06-30: 302022-09-30: 202022-12-31: 232023-03-31: 332023-06-30: 302023-09-30: 312023-12-31: 48
the quarter ended 31 Dec 20238 earlier quartersnormal: 30.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Financials: Quarterly revenue change became public on 5 Mar 2024

Acadia Pharmaceuticals reported revenue of $231.0M for the quarter ended 31 Dec 2023, 1.7× the same quarter last year.

This period
$231.0M (the quarter ended 31 Dec 2023)
Normal quarter (median of 8 earlier)
$132.7M
Typical spread (median absolute deviation)
$9.0M
How far from its usual level
+7.4
Same quarter last year
$136.5M
History used
4,932 days
2021-12-31: $130.8M2022-03-31: $115.5M2022-06-30: $134.6M2022-09-30: $130.7M2022-12-31: $136.5M2023-03-31: $118.5M2023-06-30: $165.2M2023-09-30: $211.7M2023-12-31: $231.0M
the quarter ended 31 Dec 20238 earlier quartersnormal: $132.7M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

3 Mar 2020confirmed

Confirmed across sources Institutional holdings and Filings + Financials

Acadia Pharmaceuticals (ACAD): saw 57 13F filers open a new position in the quarter ended 31 Dec 2019, 2.1× the same quarter last year, while it reported revenue of $98.3M for the quarter ended 31 Dec 2019, 1.7× the same quarter last year. Two unrelated kinds of activity within 14 days.

  • Institutional holdings: Many funds opening a new position, became public on 14 Feb 2020
  • Financials: Quarterly revenue change, became public on 3 Mar 2020
2017-12-31: 292018-03-31: 192018-06-30: 372018-09-30: 322018-12-31: 272019-03-31: 342019-06-30: 302019-09-30: 572019-12-31: 57
The quarter ended 31 Dec 2019 against the 8 quarters before it. this quarterearliernormal: 31
See the evidence (2 changes)

Institutional holdings: Many funds opening a new position became public on 14 Feb 2020

Acadia Pharmaceuticals saw 57 13F filers open a new position in the quarter ended 31 Dec 2019, 2.1× the same quarter last year.

This period
57 (the quarter ended 31 Dec 2019)
Normal quarter (median of 8 earlier)
31
Typical spread (median absolute deviation)
3.5
How far from its usual level
+5.0
Same quarter last year
27
History used
2,283 days
2017-12-31: 292018-03-31: 192018-06-30: 372018-09-30: 322018-12-31: 272019-03-31: 342019-06-30: 302019-09-30: 572019-12-31: 57
the quarter ended 31 Dec 20198 earlier quartersnormal: 31

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Financials: Quarterly revenue change became public on 3 Mar 2020

Acadia Pharmaceuticals reported revenue of $98.3M for the quarter ended 31 Dec 2019, 1.7× the same quarter last year.

This period
$98.3M (the quarter ended 31 Dec 2019)
Normal quarter (median of 8 earlier)
$58.9M
Typical spread (median absolute deviation)
$7.0M
How far from its usual level
+3.8
Same quarter last year
$59.6M
History used
3,471 days
2017-12-31: $43.6M2018-03-31: $48.9M2018-06-30: $57.1M2018-09-30: $58.3M2018-12-31: $59.6M2019-03-31: $63.0M2019-06-30: $83.2M2019-09-30: $94.6M2019-12-31: $98.3M
the quarter ended 31 Dec 20198 earlier quartersnormal: $58.9M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 23 Oct 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  2. 23 Oct 2026Filings record

    Director or officer change

  3. 6 Aug 2026Financials change

    spent $5.1M on capital projects in the quarter ended 30 Jun 2026, 17× the same quarter last year.

    Same quarter last year: $297K; its normal quarter is $342K.

    See the evidence
    This period
    $5.1M (the quarter ended 30 Jun 2026)
    Normal quarter (median of 8 earlier)
    $342K
    Typical spread (median absolute deviation)
    $308K
    How far from its usual level
    +4.7
    Same quarter last year
    $297K
    History used
    3,743 days
    2023-12-31: $02024-09-30: $70K2024-12-31: $453K2025-03-31: $02025-06-30: $297K2025-09-30: $388K2025-12-31: $4.0M2026-03-31: $5.2M2026-06-30: $5.1M
    the quarter ended 30 Jun 20268 earlier quartersnormal: $342K

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  4. 29 May 2026Filings record

    Director or officer change

  5. 12 May 2026Financials change

    spent $5.2M on capital projects in the quarter ended 31 Mar 2026, against none in the same quarter last year.

    See the evidence
    This period
    $5.2M (the quarter ended 31 Mar 2026)
    Normal quarter (median of 6 earlier)
    $184K
    Typical spread (median absolute deviation)
    $184K
    How far from its usual level
    +5.0
    Same quarter last year
    $0
    History used
    4,565 days
    2023-12-31: $02024-09-30: $70K2024-12-31: $453K2025-03-31: $02025-06-30: $297K2025-09-30: $388K2026-03-31: $5.2M
    the quarter ended 31 Mar 20266 earlier quartersnormal: $184K

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  6. 30 Apr 2026Filings record

    Director or officer change

  7. 16 Apr 2026Lobbying record

    ACADIA PHARMACEUTICALS: lobbying engagement terminated (LMH STRATEGIC SOLUTIONS) (dated 31 Dec 2025)

  8. 5 Mar 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  9. 5 Mar 2026Filings record

    Director or officer change (dated 4 Mar 2026)

  10. 20 Jan 2026Lobbying record

    ACADIA PHARMACEUTICALS INC.: lobbying engagement terminated (THE CONAFAY GROUP, LLC) (dated 31 Dec 2025)

  11. 3 Nov 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  12. 3 Nov 2025Filings record

    Director or officer change

  13. 21 Jul 2025Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['PHA']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    4821544
  14. 16 Jul 2025Lobbying record

    ACADIA PHARMACEUTICALS: new lobbying registration (LMH STRATEGIC SOLUTIONS) (dated 1 Jun 2025)

  15. 15 May 2025Institutional holdings change

    saw 57 13F filers open a new position in the quarter ended 31 Mar 2025, 1.4× the same quarter last year.

    Same quarter last year: 40; its normal quarter is 32.5.

    See the evidence
    This period
    57 (the quarter ended 31 Mar 2025)
    Normal quarter (median of 8 earlier)
    32.5
    Typical spread (median absolute deviation)
    3.5
    How far from its usual level
    +4.7
    Same quarter last year
    40
    History used
    4,200 days
    2023-03-31: 332023-06-30: 302023-09-30: 312023-12-31: 482024-03-31: 402024-06-30: 322024-09-30: 282024-12-31: 512025-03-31: 57
    the quarter ended 31 Mar 20258 earlier quartersnormal: 32.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  16. 14 Feb 2025Institutional holdings change

    saw 51 13F filers open a new position in the quarter ended 31 Dec 2024, 1.1× the same quarter last year.

    Same quarter last year: 48; its normal quarter is 31.5.

    See the evidence
    This period
    51 (the quarter ended 31 Dec 2024)
    Normal quarter (median of 8 earlier)
    31.5
    Typical spread (median absolute deviation)
    2.5
    How far from its usual level
    +5.3
    Same quarter last year
    48
    History used
    4,110 days
    2022-12-31: 232023-03-31: 332023-06-30: 302023-09-30: 312023-12-31: 482024-03-31: 402024-06-30: 322024-09-30: 282024-12-31: 51
    the quarter ended 31 Dec 20248 earlier quartersnormal: 31.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  17. 28 Jan 2025several at once

    reported $510K of lobbying spend for the quarter ended 31 Dec 2024, 2.1× the same quarter last year; it also had 17.1M shares sold short in the 15 Jan 2025 report, 2.1× the same report last year; and it saw 51 13F filers open a new position in the quarter ended 31 Dec 2024, 1.1× the same quarter last year. Three unrelated kinds of activity within 29 days.

    See the evidence (4 changes)

    Lobbying: Lobbying on a new issue became public on 20 Jan 2025

    Acadia Pharmaceuticals lobbying on a new issue.

    New
    ['TAX']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    6272795

    Lobbying: Lobbying spend jump became public on 20 Jan 2025

    Acadia Pharmaceuticals reported $510K of lobbying spend for the quarter ended 31 Dec 2024, 2.1× the same quarter last year.

    This period
    $510K (the quarter ended 31 Dec 2024)
    Normal quarter (median of 8 earlier)
    $245K
    Typical spread (median absolute deviation)
    $45K
    How far from its usual level
    +4.0
    Same quarter last year
    $240K
    History used
    2,284 days
    2022-12-31: $370K2023-03-31: $390K2023-06-30: $230K2023-09-30: $180K2023-12-31: $240K2024-03-31: $250K2024-06-30: $450K2024-09-30: $220K2024-12-31: $510K
    the quarter ended 31 Dec 20248 earlier quartersnormal: $245K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

    Check it at the source: Senate/House lobbying disclosures (LDA).

    Short interest and volume: Short interest spike became public on 28 Jan 2025

    Acadia Pharmaceuticals had 17.1M shares sold short in the 15 Jan 2025 report, 2.1× the same report last year.

    This period
    17.1M (the 15 Jan 2025 report)
    Normal report (median of 24 earlier)
    10.6M
    Typical spread (median absolute deviation)
    1.2M
    How far from its usual level
    +3.7
    Same report last year
    8.1M
    History used
    2,574 days
    2024-01-12: 8.1M2024-01-31: 7.7M2024-02-15: 9.4M2024-02-29: 10.8M2024-03-15: 10.6M2024-03-28: 11.2M2024-04-15: 11.2M2024-04-30: 12.0M2024-05-15: 12.0M2024-05-31: 12.1M2024-06-14: 12.6M2024-06-28: 11.9M2024-07-15: 11.3M2024-07-31: 11.5M2024-08-15: 10.7M2024-08-30: 10.3M2024-09-13: 9.2M2024-09-30: 8.0M2024-10-15: 8.2M2024-10-31: 9.5M2024-11-15: 10.2M2024-11-29: 9.9M2024-12-13: 9.4M2024-12-31: 10.7M2025-01-15: 17.1M
    the 15 Jan 2025 report24 earlier reportsnormal: 10.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Institutional holdings: Many funds opening a new position became public on 14 Feb 2025

    Acadia Pharmaceuticals saw 51 13F filers open a new position in the quarter ended 31 Dec 2024, 1.1× the same quarter last year.

    This period
    51 (the quarter ended 31 Dec 2024)
    Normal quarter (median of 8 earlier)
    31.5
    Typical spread (median absolute deviation)
    2.5
    How far from its usual level
    +5.3
    Same quarter last year
    48
    History used
    4,110 days
    2022-12-31: 232023-03-31: 332023-06-30: 302023-09-30: 312023-12-31: 482024-03-31: 402024-06-30: 322024-09-30: 282024-12-31: 51
    the quarter ended 31 Dec 20248 earlier quartersnormal: 31.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  18. 28 Jan 2025Short interest and volume change

    had 17.1M shares sold short in the 15 Jan 2025 report, 2.1× the same report last year.

    Same report last year: 8.1M; its normal report is 10.6M.

    See the evidence
    This period
    17.1M (the 15 Jan 2025 report)
    Normal report (median of 24 earlier)
    10.6M
    Typical spread (median absolute deviation)
    1.2M
    How far from its usual level
    +3.7
    Same report last year
    8.1M
    History used
    2,574 days
    2024-01-12: 8.1M2024-01-31: 7.7M2024-02-15: 9.4M2024-02-29: 10.8M2024-03-15: 10.6M2024-03-28: 11.2M2024-04-15: 11.2M2024-04-30: 12.0M2024-05-15: 12.0M2024-05-31: 12.1M2024-06-14: 12.6M2024-06-28: 11.9M2024-07-15: 11.3M2024-07-31: 11.5M2024-08-15: 10.7M2024-08-30: 10.3M2024-09-13: 9.2M2024-09-30: 8.0M2024-10-15: 8.2M2024-10-31: 9.5M2024-11-15: 10.2M2024-11-29: 9.9M2024-12-13: 9.4M2024-12-31: 10.7M2025-01-15: 17.1M
    the 15 Jan 2025 report24 earlier reportsnormal: 10.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  19. 20 Jan 2025Lobbying change

    reported $510K of lobbying spend for the quarter ended 31 Dec 2024, 2.1× the same quarter last year.

    Same quarter last year: $240K; its normal quarter is $245K.

    See the evidence
    This period
    $510K (the quarter ended 31 Dec 2024)
    Normal quarter (median of 8 earlier)
    $245K
    Typical spread (median absolute deviation)
    $45K
    How far from its usual level
    +4.0
    Same quarter last year
    $240K
    History used
    2,284 days
    2022-12-31: $370K2023-03-31: $390K2023-06-30: $230K2023-09-30: $180K2023-12-31: $240K2024-03-31: $250K2024-06-30: $450K2024-09-30: $220K2024-12-31: $510K
    the quarter ended 31 Dec 20248 earlier quartersnormal: $245K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

    Check it at the source: Senate/House lobbying disclosures (LDA).

  20. 20 Jan 2025Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['TAX']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    6272795
  21. 9 Jan 2025Lobbying record

    ACADIA PHARMACEUTICALS INC.: new lobbying registration (HOLLAND & KNIGHT LLP) (dated 12 Nov 2024)

  22. 11 Dec 2024Filings record

    Completed an acquisition or asset sale

  23. 20 Nov 2024Filings record

    Director or officer change

  24. 21 Oct 2024Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['TRD']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    6274707
  25. 23 Sep 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  26. 23 Sep 2024Filings record

    Director or officer change

  27. 22 Jul 2024Lobbying change

    reported $450K of lobbying spend for the quarter ended 30 Jun 2024, 2.0× the same quarter last year.

    Same quarter last year: $230K; its normal quarter is $245K.

    See the evidence
    This period
    $450K (the quarter ended 30 Jun 2024)
    Normal quarter (median of 8 earlier)
    $245K
    Typical spread (median absolute deviation)
    $15K
    How far from its usual level
    +8.4
    Same quarter last year
    $230K
    History used
    2,100 days
    2022-06-30: $230K2022-09-30: $260K2022-12-31: $370K2023-03-31: $390K2023-06-30: $230K2023-09-30: $180K2023-12-31: $240K2024-03-31: $250K2024-06-30: $450K
    the quarter ended 30 Jun 20248 earlier quartersnormal: $245K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

    Check it at the source: Senate/House lobbying disclosures (LDA).

  28. 29 May 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  29. 29 May 2024Filings record

    Director or officer change

  30. 5 Mar 2024several at once

    saw 48 13F filers open a new position in the quarter ended 31 Dec 2023, 2.1× the same quarter last year, while it reported revenue of $231.0M for the quarter ended 31 Dec 2023, 1.7× the same quarter last year. Two unrelated kinds of activity within 14 days.

    See the evidence (2 changes)

    Institutional holdings: Many funds opening a new position became public on 14 Feb 2024

    Acadia Pharmaceuticals saw 48 13F filers open a new position in the quarter ended 31 Dec 2023, 2.1× the same quarter last year.

    This period
    48 (the quarter ended 31 Dec 2023)
    Normal quarter (median of 8 earlier)
    30.5
    Typical spread (median absolute deviation)
    2.5
    How far from its usual level
    +4.7
    Same quarter last year
    23
    History used
    3,744 days
    2021-12-31: 332022-03-31: 412022-06-30: 302022-09-30: 202022-12-31: 232023-03-31: 332023-06-30: 302023-09-30: 312023-12-31: 48
    the quarter ended 31 Dec 20238 earlier quartersnormal: 30.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Financials: Quarterly revenue change became public on 5 Mar 2024

    Acadia Pharmaceuticals reported revenue of $231.0M for the quarter ended 31 Dec 2023, 1.7× the same quarter last year.

    This period
    $231.0M (the quarter ended 31 Dec 2023)
    Normal quarter (median of 8 earlier)
    $132.7M
    Typical spread (median absolute deviation)
    $9.0M
    How far from its usual level
    +7.4
    Same quarter last year
    $136.5M
    History used
    4,932 days
    2021-12-31: $130.8M2022-03-31: $115.5M2022-06-30: $134.6M2022-09-30: $130.7M2022-12-31: $136.5M2023-03-31: $118.5M2023-06-30: $165.2M2023-09-30: $211.7M2023-12-31: $231.0M
    the quarter ended 31 Dec 20238 earlier quartersnormal: $132.7M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  31. 5 Mar 2024Financials change

    reported revenue of $231.0M for the quarter ended 31 Dec 2023, 1.7× the same quarter last year.

    Same quarter last year: $136.5M; its normal quarter is $132.7M.

    See the evidence
    This period
    $231.0M (the quarter ended 31 Dec 2023)
    Normal quarter (median of 8 earlier)
    $132.7M
    Typical spread (median absolute deviation)
    $9.0M
    How far from its usual level
    +7.4
    Same quarter last year
    $136.5M
    History used
    4,932 days
    2021-12-31: $130.8M2022-03-31: $115.5M2022-06-30: $134.6M2022-09-30: $130.7M2022-12-31: $136.5M2023-03-31: $118.5M2023-06-30: $165.2M2023-09-30: $211.7M2023-12-31: $231.0M
    the quarter ended 31 Dec 20238 earlier quartersnormal: $132.7M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  32. 14 Feb 2024Institutional holdings change

    saw 48 13F filers open a new position in the quarter ended 31 Dec 2023, 2.1× the same quarter last year.

    Same quarter last year: 23; its normal quarter is 30.5.

    See the evidence
    This period
    48 (the quarter ended 31 Dec 2023)
    Normal quarter (median of 8 earlier)
    30.5
    Typical spread (median absolute deviation)
    2.5
    How far from its usual level
    +4.7
    Same quarter last year
    23
    History used
    3,744 days
    2021-12-31: 332022-03-31: 412022-06-30: 302022-09-30: 202022-12-31: 232023-03-31: 332023-06-30: 302023-09-30: 312023-12-31: 48
    the quarter ended 31 Dec 20238 earlier quartersnormal: 30.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  33. 31 Jan 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  34. 31 Jan 2024Filings record

    Director or officer change (dated 30 Jan 2024)

  35. 7 Nov 2023Financials change

    reported revenue of $211.7M for the quarter ended 30 Sep 2023, 1.6× the same quarter last year.

    Same quarter last year: $130.7M; its normal quarter is $131.2M.

    See the evidence
    This period
    $211.7M (the quarter ended 30 Sep 2023)
    Normal quarter (median of 8 earlier)
    $131.2M
    Typical spread (median absolute deviation)
    $4.3M
    How far from its usual level
    +6.1
    Same quarter last year
    $130.7M
    History used
    4,840 days
    2021-09-30: $131.6M2021-12-31: $130.8M2022-03-31: $115.5M2022-06-30: $134.6M2022-09-30: $130.7M2022-12-31: $136.5M2023-03-31: $118.5M2023-06-30: $165.2M2023-09-30: $211.7M
    the quarter ended 30 Sep 20238 earlier quartersnormal: $131.2M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  36. 25 May 2023Insiders record

    667, L.P. (director) and 5 other(s) bought 896,522 shares of ACAD ($22.7M) (dated 24 May 2023)

  37. 19 Jan 2023Lobbying change

    reported $370K of lobbying spend for the quarter ended 31 Dec 2022, 1.9× the same quarter last year.

    Same quarter last year: $200K; its normal quarter is $215K.

    See the evidence
    This period
    $370K (the quarter ended 31 Dec 2022)
    Normal quarter (median of 8 earlier)
    $215K
    Typical spread (median absolute deviation)
    $10K
    How far from its usual level
    +7.2
    Same quarter last year
    $200K
    History used
    1,553 days
    2020-12-31: $210K2021-03-31: $220K2021-06-30: $210K2021-09-30: $210K2021-12-31: $200K2022-03-31: $310K2022-06-30: $230K2022-09-30: $260K2022-12-31: $370K
    the quarter ended 31 Dec 20228 earlier quartersnormal: $215K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

    Check it at the source: Senate/House lobbying disclosures (LDA).

  38. 28 Oct 2022Filings record

    Director or officer change

  39. 20 Oct 2022Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['BUD', 'DEF']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    12627097
  40. 13 Oct 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

Showing the newest 40 of 100 entries; narrow the window or the kind of data to see older ones.

Not listed: 296 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001070494
Ticker
ACAD
Domain
acadia.com
Employer name
Acadia Pharmaceuticals Inc. (1 unverified)
Hq location
CA|SAN DIEGO|92130 (1 unverified)
Lobbying client
acadia pharmaceuticals, peck madigan jones on behalf of acadia pharmaceuticals
Name
Acadia Pharmaceuticals (France) SAS, Acadia Pharmaceuticals (Germany) GmbH, Acadia Pharmaceuticals GmbHAcadia Pharmaceuticals Holdings Inc.Acadia Pharmaceuticals (Canada) Inc, Acadia Pharmaceuticals Inc. and 8 more
Uei
D79ND8GZR3E6
Wikidata
Q4671580
Wikipedia
Acadia Pharmaceuticals
  • DOL H-1B labor condition applications and PERM certifications5 data points10 May 2021 to 10 May 2021
  • Federal lobbying disclosures (LDA)9 records, 99 data points2 Jul 2018 to 30 Sep 2026
  • SEC Form 13F institutional holdings481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)155 records5 Jan 2016 to 4 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1141 data points31 Dec 2008 to 28 Oct 2026
  • SEC Form 4 insider transactions188 records, 416 data points8 Jan 2016 to 30 Oct 2026
  • FINRA short interest (twice monthly)636 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4176 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards12 data points12 May 2011 to 19 Jan 2018
  • Wikipedia pageviews2882 data points1 Jan 2019 to 21 Nov 2026